Navigation Links
Prostate cancer signal reawakens 'sleeper agent' cells in bones
Date:1/29/2014

Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.

Metastasis is the spread of cancer from one organ to another and is a highly complex process, involving cancer cells breaking away from a primary tumour, travelling to a distant organ and colonising it. Cancer cells that fail to form a tumour in the newly-encountered tissue can fall into a dormant state.

Researchers from the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in California found that dormant prostate cancer cells within bone tissue can be reawakened to a cancerous state when exposed to RANKL, a molecule commonly produced in inflammatory cells. This reawakening can lead to metastatic prostate cancer in bone tissue.

Produced by prostate cancer cells, RANKL is a signalling molecule that has been previously linked with human prostate cancer survival. In this study, researchers engineered a clinically relevant prostate cancer cell line to overproduce RANKL. They found that these cells could significantly alter the gene expression of surrounding cells in vitro, causing them to transform into aggressive cancer cells.

Researchers then injected engineered RANKL cells directly into the blood circulation of mice, which caused dormant cells within the skeleton to re-awaken, ultimately creating tumours within the bone. When the RANKL receptor was blocked, these tumours did not form.

After examination, these tumours were found to contain both the RANKL-overproducing prostate cancer cells, as well as the dormant cells, which had been transformed to become cancerous. Remarkably, the transformed cells displayed aggressive traits that would make them resistant to the normal hormone therapies used to treat prostate cancer.

The findings are preliminary as the study used prostate cancer cells that had been engineered to overproduce RANKL. The next step is to see if other cells known to produce RANKL may also be able to recruit dormant cells to colonise bone tissue.

"We are currently embarking into clinical research with human patients," said lead researcher and postdoctoral fellow Chia-Yi (Gina) Chu, PhD. "Though more work must be done to understand how RANKL reprograms dormant cells to become cancerous, we look forward to examining its influence on promoting metastasis and secondary tumours."

Each year, a quarter of a million men die from prostate cancer worldwide (1). Bones are the most common site of prostate cancer metastases and are typically lethal in 72 percent of cases based on a five year survival rate (2). "If we can prevent prostate cancer metastasis to bone we would significantly enhance patient quality of life and increase survival rates," added Chu.


'/>"/>

Contact: Omar Jamshed
omar.jamshed@bioscientifica.com
44-014-546-42206
BioScientifica Limited
Source:Eurekalert

Related medicine news :

1. Scientists develop powerful new animal model for metastatic prostate cancer
2. Researchers identify possible explanation for link between exercise & improved prostate cancer outcomes
3. Melatonin may lower prostate cancer risk
4. Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
5. Increased risk of prostate cancer in African-American men; implications for PSA screening
6. Cleveland Clinic receives grant to study role of DNA damage in treatment-resistant prostate cancer
7. Prosvent Emerges As Preferred Treatment For Enlarged Prostate
8. Pain drugs used in prostate gland removal linked to cancer outcome, Mayo Clinic-led study finds
9. Better guidelines, coordination needed for prostate cancer specialists
10. New Treatment Now Available That Extends Life in Men with Highly Advanced Prostate Cancer
11. Inflammation in prostate may reduce cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, courtesy of leaders in the nursing and ... within the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , ...
(Date:5/26/2016)... ... ... last week’s media reports hinting at a June rate hike after the Federal Reserve’s ... interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at Georgia ... (FOMC) dot charts are of interest to the press for their noise potential,” Dhawan ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... clinical outcomes, hosted members and suppliers for its inaugural Member Conference at the ... their mission of elevating the operational health of America’s healthcare providers. , The ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John ... a new model of care for living and healing, celebrated its grand opening, today. ... in a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... and development solutions for drugs, biologics, consumer health and global clinical supply services, ... in Korea to support the company’s continued investment and strategic growth plans in ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: